ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1411

Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)

(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1387

Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 1035

Demographic and Clinical Correlates of 30 day Re-admission or Death During Admission in Patients With Rheumatologic Conditions : A Retrospective Cohort Analysis in a Single Academic Center

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1060

Demographic Risk Factors, Social Vulnerability Index, and Mortality in Patients with Systemic Lupus Erythematosus

(1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: Abstract Number: 1554

Demographic, Clinical, and Mortality Trends in Scleroderma Patients with Gastric Antral Vascular Ectasia (GAVE): A National Inpatient Analysis

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1496

Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1235

Demystifying Pain in patients with Lupus: How much is it Lupus and How much is it Other Stuff?

(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1071

Depression and Mental Health Service Gaps in Autoimmune Disease: Insights from a Simulated BRFSS Dataset

(1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: Abstract Number: 0983

Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease

(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 0905

Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases

(0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

10:30AM-12:30PM: Abstract Number: 1073

Development of a Culturally-Tailored Storytelling Intervention to Improve COVID-19 Vaccine Uptake in Black and Latinx Patients with Autoimmune and Inflammatory Rheumatic Diseases

(1055–1087) Healthcare Disparities in Rheumatology Posters

10:30AM-12:30PM: Abstract Number: 0910

Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease

(0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

10:30AM-12:30PM: Abstract Number: 1268

Development of the LupusCoach Chatbot: Results of a Focus Group

(1248–1271) Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1318

Diagnostic Delay in Rheumatoid Arthritis and its Impact on Radiographic Outcomes: A Systematic Review and Meta-analysis of 100,066 Patients

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1278

Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus

(1272–1305) Pediatric Rheumatology – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].